Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Xenoport
Evaluate
May 25, 2016
Albireo finds a way to go public
May 24, 2016
Xenoport goes out with a whimper
September 16, 2015
Tolerability data blunt Xenoport’s Tecfidera
July 09, 2015
Event – XenoPort moves closer to its date with destiny
May 21, 2013
XenoPort sees little hope beyond the Horizant
March 14, 2013
Upcoming events: March 18 – 24
January 15, 2013
Event – XenoPort gets a second shot on goal with arbaclofen
October 10, 2012
Wockardt and Arena lead small-cap gainers through nine months
July 20, 2012
Key data readouts in the second half of 2012
June 08, 2012
New Horizant approval not enough to build XenoPort's value
August 18, 2011
Encouraging signs from quality of new drugs approved so far in 2011
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
February 17, 2023
PD(L)anner – February 2023
February 09, 2023
Biopharma and Medtech Review 2022
Editor's Picks
March 13, 2023
Silicon Valley Bank: biopharma’s latest crisis
March 13, 2023
Pfizer rescues biotech
February 28, 2023
Why Pfizer (and others) will be interested in Seagen
March 04, 2023
ACC 2023 – Esperion’s outcomes win looks lacklustre
March 06, 2023
T-cell receptor behemoths consolidate? Not quite